tetracycline and Cytokine-Release-Syndrome

Chimeric antigen receptor (CAR) T cells have emerged as a promising treatment for patients with advanced B-cell cancers. However, widespread application of the therapy is currently limited by potentially life-threatening toxicities due to a lack of control of the highly potent transfused cells. Researchers have therefore developed several regulatory mechanisms in order to control CAR T cells

Topics: Antigens, Neoplasm; Cell Hypoxia; Cetuximab; CRISPR-Cas Systems; Cytokine Release Syndrome; Cytokines; Genes, Transgenic, Suicide; Humans; Immunotherapy, Adoptive; Interleukin 1 Receptor Antagonist Protein; Lymphocyte Activation; Protease Inhibitors; Protein Binding; Protein Domains; Receptors, Antigen, T-Cell, alpha-beta; Receptors, Chimeric Antigen; Rituximab; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; Tetracycline; Transcription, Genetic; Transfection; Tumor Microenvironment